NLRP3 and infection: In the present study we initially used MCC950 to block NLRP3 inflammasome activity in PAMs to determine its possible role(s) in PRRSV replication and the innate macrophagic responses during the earliest stages of infection, by treating PAMs with MCC950 (10 μM final concentration) prior to PRRSV infection.